Options Pro Says Intercept Pharmaceuticals Shares Will Go 'Much Higher' Through The End Of The Year

Shasha, the founder of Sassy Options discussed high priced stocks that have a lot of movement, specifically,

She said that she had already purchased January 2016 calls which have worked out "beautifully" thus far. Shasha added that the investment idea is still a buy-idea despite some "healthy" consolidation seen in shares recently. She added that it is often difficult to invest in weekly, bi-weekly and monthly options given expected volatility but over a full year shares are expected to go "much higher." She finally argued that Intercept is one of the only companies that hold the potential to produce meaningful therapies among patients suffering from liver issues which represents a large market.